Last reviewed · How we verify
fat orally
At a glance
| Generic name | fat orally |
|---|---|
| Also known as | water orally |
| Sponsor | German Diabetes Center |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia (PHASE1)
- A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants. (PHASE1)
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult Participants (PHASE1)
- A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults (PHASE1)
- Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women (PHASE1)
- Pharmacokinetics of Zelquistinel in Fasted or Fed State (PHASE1)
- First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fat orally CI brief — competitive landscape report
- fat orally updates RSS · CI watch RSS
- German Diabetes Center portfolio CI